Table 2.
Prevalence of the MetS in different gender group
|
Overall |
Male |
Female |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| NGT | IFG/IGT | T2D | N T | IFG/IGT | T2D | NGT | IFG/IGT | T2D | |
| N |
2341 |
1468 |
5448 |
1559 |
1172 |
3376 |
782 |
296 |
2072 |
| MetS |
509 |
920 |
4046 |
404 |
769 |
2483 |
105 |
151 |
1563 |
| 95%CI |
21.7% |
62.7% |
74.3% |
25.9% |
65.6%*** |
73.6%***### |
13.4%&&& |
51.0%***&&& |
75.4%***### |
| (20.1–23.4) |
(60.2–65.2) |
(73.1–75.4) |
(23.7–28.1) |
(62.9–68.3) |
(72.1–75.0) |
(11.03–15.82 |
(45.3-56.8) |
(73.6-77.3) |
|
| OR | Ref | 6.078 |
10.435 |
Ref | 5.486 |
7.956 |
Ref | 6.752 |
20.018 |
| (5.261–7.020) | (9.297–11.711) | (4.650–6.472) | (6.940–9.120) | (4.971-9.172) | (15.928-25.157) | ||||
Compared with NGT *P<0.05, **P<0.01, ***P<0.001;
Compared with IFG/IGT #P<0.05, ##P<0.01, ###P<0.001;
Compared with male group &P<0.05, &&P<0.01, &&&P<0.001.